This cluster groups 2 independently calculated changes: Cash & equivalents decreased 88.3%; Operating cash flow decreased 38.2%.
2 evidence-backed components· Pharmaceutical Preparations
RESEARCH SNAPSHOTTuHURA Biosciences, Inc./NV's latest supported as-filed period reports revenue of $0. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Cash & equivalents decreased 88.3%; Operating cash flow decreased 38.2%.
2 evidence-backed componentsFree-cash-flow proxy changed -40.2% from the comparable as-filed period.
Each point keeps the date investors could first observe it and its accession.
HURA · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-383797SEC ↗8-KAug 21, 2026Period Aug 20, 20260001193125-26-361272SEC ↗8-KAug 19, 2026Period Aug 18, 20260001193125-26-357087SEC ↗10-QAug 14, 2026Period Jun 30, 20260001193125-26-350451SEC ↗8-KAug 14, 2026Period Aug 14, 20260001193125-26-350425SEC ↗8-KAug 13, 2026Period Aug 7, 20260001193125-26-349540SEC ↗8-KJul 29, 2026Period Jul 28, 20260001193125-26-324174SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| May 28, 2026Filed May 29, 2026 | Bianco James A.Chief Executive Officer | GiftDirect | 150,000 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Operating cash flow changed -38.2% from the comparable as-filed period.
Shares outstanding changed +27.3% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Current liabilities changed -39.0% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Research & development changed +34.4% from the comparable as-filed period.
Current assets changed -86.8% from the comparable as-filed period.
Current ratio changed -78.4% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-26-297668